Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?

US Lazertinib Decision A Catalyst

 
• By Jung Won Shin
signs of recovery
Korean firms Opt For Rights Offerings Amid Shoots of recovery in funding • Source: Shutterstock

More from South Korea

More from Focus On Asia